Dr. Hossein Borghaei

MD – Oncologist & Hermatologist

Profile

Dr. Hossein Borghaei

MD, University of Minnesota Medical School
Residency in Internal Medicine, Hennepin County Medical Center
Fellowship in Hematology & Oncology, University of Minnesota

Current Role At Neovita

Dr. Borghaei collaborates with NeoVita’s research division to advance immunotherapy options for patients with lung cancer.

Expertise & Specialization

• DO. Philadelphia College of Osteopathic Medecine
• MS in Clinical Microbiology, Drexel University
• Fellowship in Oncology, Fox Chase Cancer Center

Memberships & Affiliation

• American Society of Hematology (ASH)
• American Society of Clinical Oncology (ASCO)

Biography

Dr. Hossein Borghaei is a leading thoracic medical oncologist based at Neovita oncology Cancer Center, where he currently holds several senior roles. He is Chief of the Division of Thoracic Medical Oncology, a Professor in the Department of Hematology/Oncology, and the Gloria and Edmund M. Dunn Chair in Thoracic Malignancies. He earned his medical degree from the Philadelphia College of Osteopathic Medicine, after which he completed a residency in Internal Medicine at Graduate Hospital in Philadelphia. He then undertook fellowship training in hematology and medical oncology at Fox Chase. U.S. News Health+2Fox Chase Cancer Center+2.Dr. Borghaei’s work spans both clinical practice and research: he directs a laboratory focused on developing new monoclonal antibodies and immune-modulating therapies for lung cancer.. He has been principal investigator on clinical trials, including a Phase III trial that provided evidence for the effectiveness of nivolumab in advanced non-squamous non-small cell lung cancer after prior chemotherapy. American Lung Association+1He is also active in professional societies and national‐level committees: a member of the thoracic core committee of the Eastern Cooperative Oncology Group (ECOG), and formerly a member of the Non-Small Cell Lung Cancer panel of the National Comprehensive Cancer Network (NCCN). American Lung Association+1 Among his accolades are an ASCO Young Investigator Award, an ASCO Career Development Award, and the Robert Krigel Teaching Award at Neovita for his contributions to medical education. American Lung Association+1.His treatment philosophy emphasizes seeing the patient as a whole, not just the disease: integrating clinical trials, immunotherapy, multidisciplinary care, and patient and family engagement are all central to his approach

Career highlights & Achievements

Dr. Hossein Borghaei has earned international recognition for his contributions to thoracic oncology, particularly in advancing immunotherapy for lung cancer. He served as principal investigator of the pivotal Phase III clinical trial that established nivolumab as an effective treatment for advanced non-squamous non-small cell lung cancer after chemotherapy, helping change the standard of care (lung.org). At Neovita, he directs a translational research laboratory investigating novel monoclonal antibodies and immune-modulating agents, bridging laboratory discoveries to clinical practice His leadership roles include Chief of the Division of Thoracic Medical Oncology and the Gloria and Edmund M. Dunn Chair in Thoracic Malignancies. Dr. Borghaei has been recognized with an ASCO Young Investigator Award, an ASCO Career Development Award, and the Robert Krigel Teaching Award at Fox Chase for his dedication to research and mentorship (lung.org). He is also active nationally, serving on the thoracic core committee of the Eastern Cooperative Oncology Group (ECOG) and previously on the NCCN Non-Small Cell Lung Cancer panel, shaping treatment guidelines that impact care worldwide.